Soleus Capital Management, L.P. Fibrogen Inc Transaction History

Soleus Capital Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$15.95 - $25.18 $255,200 - $402,880	16,000 Added 14.1%	129,463 $2.42 Million
Q4 2022 Feb 14, 2023	SELL	$13.27 - $17.73 $1.6 Million - $2.14 Million	-120,563 Reduced 51.52%	113,463 $1.82 Million
Q3 2022 Nov 14, 2022	SELL	$11.4 - $14.6 $777,480 - $995,720	-68,200 Reduced 22.57%	234,026 $3.05 Million
Q2 2022 Aug 15, 2022	SELL	$7.94 - $12.96 $6.05 Million - $9.88 Million	-762,130 Reduced 71.6%	302,226 $3.19 Million
Q1 2022 May 16, 2022	SELL	$12.02 - $16.79 $5.84 Million - $8.16 Million	-486,141 Reduced 31.35%	1,064,356 $12.8 Million
Q4 2021 Feb 14, 2022	BUY	$9.93 - $15.39 $15.4 Million - $23.9 Million	1,550,497 New	1,550,497 $21.9 Million

46.8M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $53.4M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.